Duchenne Muscular Dystrophy
A severe, progressive dystrophinopathy affecting skeletal, respiratory, and cardiac muscle, with advances in gene-targeted therapies expanding treatment options.
- X-Linked Recessive (DMD Gene)
- Approved Gene Therapy Available
- Multidisciplinary Care Required
- Typical Onset
- Ages 2-5 years
- Inheritance Pattern
- X-linked Recessive
- Key Gene
- DMD (dystrophin)
- Advanced Therapy Anchor
- Exon-Skipping, Gene Therapy, Corticosteroids
Condition Overview
Duchenne Muscular Dystrophy (DMD) is a severe, progressive inherited muscle disease caused by mutations in the DMD gene that prevent production of functional dystrophin, a protein critical for maintaining the structural integrity of muscle cells. It is the most common and most severe form of childhood muscular dystrophy.
DMD typically becomes apparent between ages 2 and 5, with progressive weakness affecting the hips and shoulders first, eventually involving all skeletal muscles, the diaphragm, and the heart. Without intervention, loss of independent walking typically occurs in the early teenage years, though corticosteroid therapy and other treatments have meaningfully extended ambulation and overall function.
Major advances in recent years, including exon-skipping therapies and an approved gene therapy, have changed the treatment landscape, making early diagnosis and access to specialist multidisciplinary care more important than ever.
Types and Subtypes
DMD is primarily defined by complete or near-complete absence of functional dystrophin, but presentation and associated features can vary.
Symptoms and Signs
DMD presents with progressive muscle weakness that follows a relatively predictable pattern over childhood and adolescence.
Causes and Risk Factors
DMD is caused by mutations in the DMD gene, located on the X chromosome, that result in absent or non-functional dystrophin protein.
Diagnosis and Investigations
Diagnosis combines clinical evaluation, laboratory testing, and genetic confirmation, with early diagnosis important given the availability of disease-modifying treatments.
Disease Course and Functional Classification
DMD does not use a tumor-style staging system. Clinicians instead track functional status (ambulatory vs non-ambulatory) and organ involvement to guide management.
Standard Treatment Approach
There is no cure for DMD, but a structured multidisciplinary treatment approach has been shown to meaningfully extend function and improve quality of life.
Advanced and Emerging Treatment Options
DMD has seen significant therapeutic advances in recent years, with both approved gene-targeted therapies and an active research pipeline.
Exon-Skipping Therapy
Antisense Oligonucleotide Exon-Skipping Agents
Approved therapies designed to skip specific exons and restore partial dystrophin production, applicable to patients with amenable mutations.
Gene Therapy
Micro-Dystrophin Gene Replacement Therapy
An approved one-time gene therapy delivering a shortened, functional dystrophin gene, available for eligible younger ambulatory patients in certain regions.
Pharmacologic Therapy
Novel Anti-Inflammatory and Muscle-Protective Agents
Newer agents aimed at reducing muscle inflammation and damage are available or under active study as adjuncts to corticosteroid therapy.
Clinical Trial Participation
Next-Generation Gene and Cell Therapy Trials
Ongoing trials are exploring expanded gene therapy eligibility, combination approaches, and novel delivery methods.
Genetic and Molecular Markers
Precise genetic characterization is essential in DMD, directly determining eligibility for several approved and investigational therapies.
When a Second Opinion May Be Important
Given the rapidly evolving treatment landscape for DMD, specialist input can be especially valuable.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in DMD has improved meaningfully with modern multidisciplinary care, corticosteroid therapy, and gene-targeted treatments, though the disease remains progressive and life-limiting for many patients.
Supportive Care and Living with Duchenne Muscular Dystrophy
Comprehensive, multidisciplinary supportive care is central to maintaining function and quality of life throughout the course of DMD.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families with a Duchenne muscular dystrophy diagnosis access specialist neuromuscular second opinions, clarify eligibility for exon-skipping and gene therapy, and connect with relevant clinical trial opportunities.
Get a free case reviewFrequently Asked Questions
Duchenne Muscular Dystrophy is a severe inherited muscle disease caused by DMD gene mutations that prevent production of dystrophin, leading to progressive weakness affecting skeletal, respiratory, and cardiac muscle.
Early signs often include delayed walking, frequent falls, difficulty rising from the floor (Gowers' sign), and calf muscle enlargement, typically noticed between ages 2 and 5.
Yes, it follows an X-linked recessive inheritance pattern and almost exclusively affects males, though about one-third of cases arise from new mutations without a family history.
Diagnosis typically involves markedly elevated creatine kinase levels followed by genetic testing of the DMD gene to confirm a mutation causing absent dystrophin production.
There is currently no cure, but treatment options including corticosteroids, exon-skipping therapies, and an approved gene therapy have meaningfully changed disease management and extended function for many patients.
Exon-skipping therapies are designed to help cells skip over specific faulty sections of the DMD gene, allowing production of a partially functional, shortened dystrophin protein in patients with amenable mutations.
Yes, cardiomyopathy and respiratory muscle weakness are expected complications as the disease progresses, making regular cardiac and pulmonary monitoring an essential part of care.
Care typically involves neuromuscular neurology, cardiology, pulmonology, orthopedics, physical therapy, and genetic counseling, coordinated through a multidisciplinary clinic where available.
Yes, with modern multidisciplinary care many individuals with DMD live well into adulthood, though the disease remains progressive and requires ongoing specialist management.
Yes. CancerFax can help coordinate review of genetic test results, connect families with specialist neuromuscular second opinions, and provide information on exon-skipping therapy, gene therapy eligibility, and clinical trial opportunities, including cross-border coordination where appropriate.
Have a Duchenne Muscular Dystrophy Diagnosis?
Get expert review of genetic test results to clarify eligibility for exon-skipping and gene therapy options.